ReviewCardio-oncology (London, England)2026
Mortality predictors in cancer patients undergoing transcatheter aortic valve implantation for aortic stenosis: a systematic review and meta-analysis.
Review in Cardio-oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe coexistence of cancer and aortic stenosis is increasingly common in elderly patients, presenting unique challenges for management. Transcatheter aortic valve implantation (TAVI) offers a less invasive alternative to surgical valve replacement, but the impact of various clinical factors on post-TAVI mortality in cancer patients remains unclear.
objectiveTo systematically review and meta-analyze the predictors of mortality in cancer patients undergoing TAVI for aortic stenosis.
methodsA comprehensive literature search was conducted in Scopus, PubMed, Web of Science, and Embase up to May 2025. Studies assessing mortality predictors in cancer patients post-TAVI were included. Data extraction and quality assessment were performed independently by two reviewers. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using random-effects models. Sensitivity analyses addressed within-study correlation assumptions, and heterogeneity was assessed using I² and τ² statistics.
resultsFive high-quality case-control studies, encompassing over 7,000 patients, were included. Advanced NYHA class (III/IV), prior myocardial infarction, atrial fibrillation, COPD, diabetes mellitus, and higher STS scores were robustly associated with increased mortality. Active cancer conferred a significantly higher mortality risk (HR 1.64, 95% CI: 1.17-2.30), while preserved left ventricular ejection fraction and renal function were linked to improved survival. Most predictors remained stable across sensitivity analyses, although the impact of cancer status varied with correlation assumptions.
conclusionBoth traditional cardiovascular and cancer-specific factors significantly influence mortality in cancer patients undergoing TAVI. These findings underscore the need for individualized, multidisciplinary risk assessment and highlight the importance of further research to refine patient selection and optimize outcomes in this growing patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.